8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
Apr 17, 2026·SEC
Material company update
Apr 2, 2026·SEC
Tyra Biosciences, Inc.(TYRA)Earnings, Financials & Key Ratios
TYRA•NASDAQ
$31.94
Price updated Jul 7, 2026
AboutTyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.Show more
- Revenue$0
- EBITDA-$132M-27.6%
- Net Income-$120M-38.7%
- EPS (Diluted)-2.01-33.1%
- ROE-39.83%-26.1%
TYRA Price & Volume
Tyra Biosciences, Inc. (TYRA) stock price & volume — 10-year historical chart
Loading chart...
Accelerating Clinical Burn Outpaces Capital Preservation Efforts
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical Trial Execution Risk
Key Thesis Takeaways
- Tyra Biosciences remains in a high-risk, pre-revenue development phase characterized by an aggressive expansion of clinical trial expenditures that significantly outpaces historical spending.
- The company's reliance on external capital to fund its $33.3 million quarterly R&D burn suggests a precarious long-term funding model absent of near-term commercialization.
- Investors should monitor the narrowing liquidity buffer, which has declined from $254.4 million in 2024Q1 to $85.0 million as of 2026Q1, as it necessitates ongoing, potentially dilutive financing to sustain operations.
Verdict Logic
the company's cash position has dropped by approximately 66.6% since 2024Q1, signaling an unsustainable trajectory of capital consumption that poses significant dilution risks to current shareholders.
TYRA Growth Metrics
Tyra Biosciences, Inc. (TYRA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-35.95%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-33.74%
Return on Capital
10 Years-57.86%
5 Years-30.39%
3 Years-38.16%
Last Year-43.28%
TYRA Recent Earnings
Tyra Biosciences, Inc. (TYRA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.64-6.7%
$0.60
Rev
—
—
Q2 2026
Mar 2, 2026Metric
Actual
Est
EPS
$0.57-5.6%
$0.54
Rev
—
—
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.50+0.0%
$0.50
Rev
—
—
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.47+11.3%
$0.53
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.64vs $0.60-6.7% | — |
| Q2 2026 | Mar 2, 2026 | $0.57vs $0.54-5.6% | — |
| Q4 2025 | Nov 5, 2025 | $0.50vs $0.50+0.0% | — |
| Q3 2025 | Aug 14, 2025 | $0.47vs $0.53+11.3% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Tyra Biosciences, Inc. (TYRA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $31.94 | $1.9B | -15.89 | — | — | -39.83% | — | |
| $11.65 | $372.78M | 5.07 | 6774.96% | -256.6% | -17.04% | — | |
| $123.77 | $9.1B | -21.16 | — | — | -42.78% | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — | |
| $90.00 | $6.83B | -26.87 | -12.38% | -654.43% | -50.62% | — | |
| $18.36 | $5.71B | -41.73 | — | — | -77.01% | — |
Compare TYRA vs Peers
Tyra Biosciences, Inc. (TYRA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TYRA SEC Filings & Documents
Tyra Biosciences, Inc. (TYRA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when TYRA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TYRA Frequently Asked Questions
Tyra Biosciences, Inc. (TYRA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is TYRA profitable?
Tyra Biosciences, Inc. (TYRA) reported a net loss of $131.1M for fiscal year 2025.
Dividend & Returns
What is TYRA's return on equity?
Tyra Biosciences, Inc. (TYRA) has a return on equity (ROE) of -39.8%. Negative ROE indicates the company is unprofitable.
What is Tyra Biosciences, Inc.'s free cash flow?
Tyra Biosciences, Inc. (TYRA) had negative free cash flow of $102.5M in fiscal year 2025, likely due to heavy capital investments.